We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Twins Study Reveals Fatty Liver Disease Heritability

By LabMedica International staff writers
Posted on 13 Oct 2015
A study involving identical and fraternal twins showed that incidence of fatty liver disease was equivalent for the identical twins but not correlated among the fraternal twins, suggesting that the syndrome might be inherited.

Since little is known about the heritability of hepatic fibrosis and hepatic steatosis, investigators at the University of California, San Diego (USA) carried out a study utilizing a well-characterized cohort of twins to determine to what extent fatty liver disease was inheritable.

The investigators collected data on medical history, physical examinations, fasting laboratory test results, and liver health from 60 pairs of twins (42 monozygotic or identical and 18 dizygotic or fraternal). More...
All participants underwent an advanced magnetic resonance imaging (MRI) examination of the liver from January 2012 through January 2015. Hepatic steatosis was quantified noninvasively by MRI and determined based on the proton-density fat fraction (MRI-PDFF); liver fibrosis was measured based on stiffness measured by magnetic resonance elastography.

Results published in the August 20, 2015, online edition of the journal Gastroenterology revealed that the presence of hepatic steatosis correlated between identical twins but not between fraternal twins. The level of liver fibrosis also correlated between identical twins but not between fraternal twins.

"The most common known causes of hepatic fibrosis have been viral hepatitis C infections, alcohol abuse, poor diet, and obesity and nonalcoholic steatohepatitis or NASH, which resembles alcoholic liver disease but occurs in people who drink little or no alcohol," said first author Dr. Rohit Loomba, associate professor of clinical medicine at the University of California, San Diego. "We found, however, that hepatic fibrosis and steatosis (infiltration of liver cells with fat) are strong genetic traits. At around 50% heritability, they are more genetic than body mass index. This evidence that hepatic steatosis and hepatic fibrosis are heritable traits has major implications. It means that we can now look for the relevant genes as potential therapeutic targets."

Related Links:

University of California, San Diego



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.